How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Medical Second Opinion Market
- By Service Type: On-demand Second Opinion, Pre-treatment Second Opinion, Post-treatment Second Opinion, Chronic Disease Management Opinion, Surgical Opinion
- By Delivery Mode: Telemedicine/Virtual Consultation, In-person Consultation, Hybrid Consultation
- By End User: Individual Patients, Healthcare Providers, Insurance Companies, Employers/Corporate Wellness Programs
- By Specialty: Oncology, Cardiology, Neurology, Orthopedics, Radiology
- By Provider Type: Independent Medical Experts, Hospital-affiliated Specialists, Telehealth Platforms, Academic Medical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - On-demand Second Opinion leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 11 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Medical Second Opinion Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Delivery Mode 3
End User 4
Specialty 5
Provider Type 4
Companies profiled
Grand Rounds Health (now included in Included Health)
Best Doctors (a Teladoc Health company)
Mayo Clinic
Johns Hopkins Medicine
Cleveland Clinic
MDLIVE
2nd.MD
HealthTap
MedOpinions
CureMetrix
Mediguide
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Grand Rounds Health (now included in Included Health)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Best Doctors (a Teladoc Health company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mayo Clinic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Johns Hopkins Medicine
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cleveland Clinic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MDLIVE
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →2nd.MD
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →HealthTap
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MedOpinions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CureMetrix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Mediguide
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,628M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- On-demand Second Opinion31.2
- Pre-treatment Second Opinion9.7
- Post-treatment Second Opinion20.5
- Chronic Disease Management Opinion22.0
- Surgical Opinion16.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,032M → $1,541M · 5.1%
Europe$719.3M → $1,144M · 6.0%
Asia Pacific$656.8M → $1,001M · 5.4%
Latin America$406.6M → $600.2M · 5.0%
Middle East and Africa$312.7M → $513.0M · 6.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.972026
4.992027
4.992028
5.002029
5.032030
5.042031
5.052032
5.062033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Grand Rounds Health (now included in Included Health)18.9
- Best Doctors (a Teladoc Health company)15.4
- Mayo Clinic4.0
- Johns Hopkins Medicine11.7
- Cleveland Clinic12.6
- MDLIVE9.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type29.7%
Delivery Mode9.6%
End User24.5%
Specialty10.6%
Provider Type25.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe23.8
- Asia Pacific20.9
- Latin America12.5
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Grand Rounds Health (now included in Included Health) | 90 | 85 | 87 | 92 | 81 | 80 | 86 |
| Best Doctors (a Teladoc Health company) | 89 | 85 | 72 | 69 | 92 | 68 | 79 |
| Mayo Clinic | 85 | 87 | 82 | 80 | 66 | 79 | 80 |
| Johns Hopkins Medicine | 82 | 73 | 58 | 76 | 77 | 64 | 72 |
| Cleveland Clinic | 57 | 70 | 66 | 68 | 63 | 75 | 67 |
| MDLIVE | 56 | 57 | 68 | 48 | 49 | 71 | 58 |
| 2nd.MD | 43 | 65 | 63 | 63 | 61 | 47 | 57 |
| HealthTap | 39 | 41 | 58 | 51 | 56 | 36 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Grand Rounds Health (now included in Included Health)
- Best Doctors (a Teladoc Health company)
- Mayo Clinic
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Grand Rounds Health (now included in Included Health) | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Best Doctors (a Teladoc Health company) | ◐ | ✓ | − | ◐ | ✓ | − |
| Mayo Clinic | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Johns Hopkins Medicine | ◐ | ◐ | − | ✓ | ◐ | ◐ |
| Cleveland Clinic | ◐ | − | − | ✓ | − | ◐ |
| MDLIVE | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| 2nd.MD | − | ✓ | ◐ | ◐ | − | ◐ |
| HealthTap | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Grand Rounds Health (now included in Included Health)86
2Mayo Clinic80
3Best Doctors (a Teladoc Health company)79
4Johns Hopkins Medicine72
5Cleveland Clinic67
6MDLIVE58
72nd.MD57
8HealthTap47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Grand Rounds Health (now included in Included Health)Best Doctors (a Teladoc Health company)Mayo Clinic
Challenger2
Strong scale, closing on the leaders.
Johns Hopkins MedicineCleveland Clinic
Contender2
Focused players with pockets of strength.
MDLIVE2nd.MD
Niche1
Specialists in a single segment or region.
HealthTap
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Medical Second Opinion Market — a $87M beachhead inside a $1.17B market.
Beachhead (SOM)$87Mobtainable near-term
Serviceable (SAM)$460Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
On-demand Second Opinion
Best fit — highest urgency & budget in Service Type.
Economic buyer76 fit
Pre-treatment Second Opinion
Strong fit — clear ROI and a fast path to value.
End user67 fit
Post-treatment Second Opinion
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Delivery Mode & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Medical Second Opinion Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation11%
Closed-won8%
$8.2KCAC
$40KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Medical Second Opinion Market is a resilient opportunity — $8.05B by 2033, compounding at 5.6%.
TAM · 2025$5.22Btoday
TAM · 2033$8.05Bforecast
CAGR5.6%2027–2033
Cumulative$58.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.05BTotal addressable market
SAM$3.25BServiceable available market
SOM$634MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.6% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.05BLarge & growingTAM by 2033 at 5.6% CAGR
$3.25BServiceable nowreachable with today’s model
$634MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.28BBear3.6% CAGR
$8.05BBase5.6% CAGR
$10.3BBull7.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Delivery Mode optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Medical Second Opinion Market — a $10.2B market by 2033. Plan: grow share from 6.7% to 12.9%.
Market size · 2033$10.2Btotal addressable
Market CAGR10.7%2027–2033
Target share12.9%from 6.7% today
Revenue ambition$1.31Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 12.9% | On track |
| Revenue | $737M | $1.31B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 31.1% | 41.0% | Behind |
| Customer retention | 88.1% | 94.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Delivery Mode capability
A defensible second engine — invest in Delivery Mode to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Delivery Mode
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $165M capacity & capability investment
- Greenlight bolt-on M&A in Delivery Mode
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Medical Second Opinion Market conversation — a $837M market you can size, segment and defend in minutes.
Market size · 2033$837Mtotal opportunity
Growth6.7%CAGR to 2033
Addressable buyers1,522+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$90K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Grand Rounds Health (now included in Included Health)Best Doctors (a Teladoc Health company)Mayo ClinicJohns Hopkins MedicineCleveland ClinicMDLIVE2nd.MDHealthTap+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Medical Second Opinion Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Medical Second Opinion Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Medical Secondary Packaging Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMedical-Secondary Gloves Market
Market size, share, segmentation and regional forecast.
$860M market · 2025 base year
View reportMedical Seamless Gas Cylinders Market
Market size, share, segmentation and regional forecast.
$653M market · 2025 base year
View reportMedical Seals Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMedical Sealing Machine Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportMedical Scrub Uniform Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportMedical Scroll Compressors Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportMedical Scooters Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportMedical Scoliosis Corrector Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMedical Scheduling Solution Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMedical Scavenging System Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMedical Scar Stickers Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.